These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 21323894)

  • 1. Novel classes of antibiotics or more of the same?
    Coates AR; Halls G; Hu Y
    Br J Pharmacol; 2011 May; 163(1):184-94. PubMed ID: 21323894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multidrug-resistant gram-negative organisms: a review of recently approved antibiotics and novel pipeline agents.
    Provenzani A; Hospodar AR; Meyer AL; Leonardi Vinci D; Hwang EY; Butrus CM; Polidori P
    Int J Clin Pharm; 2020 Aug; 42(4):1016-1025. PubMed ID: 32638294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Will new antimicrobials overcome resistance among Gram-negatives?
    Bassetti M; Ginocchio F; Mikulska M; Taramasso L; Giacobbe DR
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):909-22. PubMed ID: 21973303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotics in the clinical pipeline in 2011.
    Butler MS; Cooper MA
    J Antibiot (Tokyo); 2011 Jun; 64(6):413-25. PubMed ID: 21587262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breaking barriers: expansion of the use of endolysins as novel antibacterials against Gram-negative bacteria.
    Briers Y; Lavigne R
    Future Microbiol; 2015; 10(3):377-90. PubMed ID: 25812461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibiotics in phase II and III clinical trials.
    Coates AR; Halls G
    Handb Exp Pharmacol; 2012; (211):167-83. PubMed ID: 23090602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leaks in the Pipeline: a Failure Analysis of Gram-Negative Antibiotic Development from 2010 to 2020.
    Prasad NK; Seiple IB; Cirz RT; Rosenberg OS
    Antimicrob Agents Chemother; 2022 May; 66(5):e0005422. PubMed ID: 35471042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic Understanding Enables the Rational Design of Salicylanilide Combination Therapies for Gram-Negative Infections.
    Copp JN; Pletzer D; Brown AS; Van der Heijden J; Miton CM; Edgar RJ; Rich MH; Little RF; Williams EM; Hancock REW; Tokuriki N; Ackerley DF
    mBio; 2020 Sep; 11(5):. PubMed ID: 32934086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic adjuvants: an alternative approach to overcome multi-drug resistant Gram-negative bacteria.
    Liu Y; Li R; Xiao X; Wang Z
    Crit Rev Microbiol; 2019 May; 45(3):301-314. PubMed ID: 30985240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New antibacterial agents for treating infections caused by multi-drug resistant Gram-negative bacteria.
    O'Neill AJ
    Expert Opin Investig Drugs; 2008 Mar; 17(3):297-302. PubMed ID: 18321229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Decision Tree Using Patient Characteristics to Predict Resistance to Commonly Used Broad-Spectrum Antibiotics in Children With Gram-Negative Bloodstream Infections.
    Sick-Samuels AC; Goodman KE; Rapsinski G; Colantouni E; Milstone AM; Nowalk AJ; Tamma PD
    J Pediatric Infect Dis Soc; 2020 Apr; 9(2):142-149. PubMed ID: 30690525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infections by multidrug-resistant Gram-negative Bacteria: What's new in our arsenal and what's in the pipeline?
    Koulenti D; Song A; Ellingboe A; Abdul-Aziz MH; Harris P; Gavey E; Lipman J
    Int J Antimicrob Agents; 2019 Mar; 53(3):211-224. PubMed ID: 30394301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What is in the pipeline for Gram-negative pathogens?
    Talbot GH
    Expert Rev Anti Infect Ther; 2008 Feb; 6(1):39-49. PubMed ID: 18251663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mastering the Gram-negative bacterial barrier - Chemical approaches to increase bacterial bioavailability of antibiotics.
    Ropponen HK; Richter R; Hirsch AKH; Lehr CM
    Adv Drug Deliv Rev; 2021 May; 172():339-360. PubMed ID: 33705882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recent progress in development of antibiotics against Gram-negative bacteria].
    Xu ZQ; Xu ZY
    Yao Xue Xue Bao; 2013 Jul; 48(7):993-1004. PubMed ID: 24133966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjunctive transferrin to reduce the emergence of antibiotic resistance in Gram-negative bacteria.
    Luna BM; Ershova K; Yan J; Ulhaq A; Nielsen TB; Hsieh S; Pantapalangkoor P; Vanscoy B; Ambrose P; Rudin S; Hujer K; Bonomo RA; Actis L; Skaar EP; Spellberg B
    J Antimicrob Chemother; 2019 Sep; 74(9):2631-2639. PubMed ID: 31170282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymyxin Derivatives that Sensitize Gram-Negative Bacteria to Other Antibiotics.
    Vaara M
    Molecules; 2019 Jan; 24(2):. PubMed ID: 30641878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of an expanded microarray for detecting antibiotic resistance genes in a broad range of gram-negative bacterial pathogens.
    Card R; Zhang J; Das P; Cook C; Woodford N; Anjum MF
    Antimicrob Agents Chemother; 2013 Jan; 57(1):458-65. PubMed ID: 23129055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review.
    Sumi CD; Heffernan AJ; Lipman J; Roberts JA; Sime FB
    Clin Pharmacokinet; 2019 Nov; 58(11):1407-1443. PubMed ID: 31325141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for the empirical management of infection in cancer patients with emphasis on the emergence of resistant gram-negative bacteria.
    Klastersky J; Georgala A
    Crit Rev Oncol Hematol; 2014 Dec; 92(3):268-78. PubMed ID: 25151213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.